Dr. Francis Sessions Cole, III, is a neonatologist, meaning he works with the smallest and most helpless patients – newborn infants, many of whom are born premature. While there are many conditions treated in the neonatal care unit, genetic lung diseases are common. Many of these cases are fatal and there is an obvious shortage of infant lungs that can be used for transplants. This leads to Dr. Cole having an extremely difficult role and often a heartbreaking reality. Dr. Cole handles his emotions by drawing inspiration from the resilience and strength of the babies’ families.
Diagnosing a rare or less common disease is a great challenge for patients who have a rare genetic disorders. Helping to address this diagnosis challenge is The Undiagnosed Disease Network (UDN), which consists of twelve clinical sites that evaluate patients who have been on an extensive diagnostic odysseys. The odyssey that these patients undergo to seek a diagnosis often encompasses many years and requires numerous specialists and centers. Without a diagnosis patients are often overlooked in the healthcare system. Therefore, establishing a diagnosis is a critical first step in beginning patient care. The UDN brings together clinical and research experts from across the United States to solve the most challenging medical mysteries using advanced technologies. To date, the UDN has provided a diagnosis for about one third of their 5000 patients, a small percentage of the estimated 30 million patients in the US who have a disease that is undiagnosed. Clearly there is still a significant amount of work that needs to be complete to address a larger number of undiagnosed patients. Providing undiagnosed patients with access to whole genome sequencing and genetic counselors are good first steps to addressing this need.
Dr. Cole is passionate about addressing this need and helping patients get a diagnosis. He spearheaded Washington University in St. Louis’ (WUSTL) efforts to become a UDN site. This included uniting the many resources, people, and diagnostics capabilities available at WUSTL under a single program.
One of the most common questions families ask when they obtain a diagnosis is, “Now what do we do?”. That’s where n-Lorem can help. n-Lorem discovers and develops personalized experimental ASO medicines for nano-rare patients. Patients who believe they might be a candidate for n-Lorem should discuss with their genetic counselor or physician if ASO technology could help. If so, the physician will need to complete a formal application to treatment with n-Lorem. Because n-Lorem works closely with the treating physician and their institution and there is a large amount of information required to adequately review an application, n-Lorem requests that the physician submit the application and not the patient. Once submitted, each application is review by the Access to Treatment Committe (ATTC), which is made up of pharmaceutical executives, physicians, academic professors, patient advocates, and a bioethicist. This committee reviews applications from physicians or organizations, like the UDN, to treat diagnosed, genetically confirmed nano-rare disease patients.